

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 26, 2009

**QUESTCOR PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**California**  
(State or Other Jurisdiction  
of Incorporation)

**001-14758**  
(Commission File Number)

**33-0476164**  
(I.R.S. Employer  
Identification No.)

**3260 Whipple Road Union City, California**  
(Address of Principal Executive Offices)

**94587**  
(Zip Code)

Registrant's telephone number, including area code: **(510) 400-0700**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers****Determination of 2008 Cash Bonuses for Executive Officers**

On February 26, 2009, the Board of Directors (the "Board") of Questcor Pharmaceuticals, Inc. (the "Company"), based on the recommendation of the Board's Compensation Committee (the "Compensation Committee"), approved the 2008 cash bonuses for the Company's executive officers. The 2008 cash bonuses were determined based on the executive officer's level of satisfaction of the management performance objectives established and tailored for such executive officer by the Compensation Committee for the Company's 2008 fiscal year. The table below sets forth the cash bonuses for the following executive officers:

<u>Name</u>	<u>Title</u>	<u>2008 Cash Bonus</u>
Don M. Bailey	President and Chief Executive Officer	\$429,188
Stephen L. Cartt	Executive Vice President, Corporate Development	\$252,500
David J. Medeiros	Senior Vice President, Pharmaceutical Operations	\$171,250
Gary M. Sawka <sup>(1)</sup>	Senior Vice President, Finance and Chief Financial Officer	\$ 31,933

(1) Mr. Sawka commenced employment with the Company on September 10, 2008.

**Grant of Options to Executive Officers**

On February 26, 2009, the Board, based on the recommendation of the Compensation Committee, approved the grant of options to purchase the Company's common stock to the Company's executive officers under the Company's 2006 Equity Incentive Plan. The table below sets forth the stock option grants approved by the Board:

<u>Name</u>	<u>Title</u>	<u>Shares Subject to Option</u>
Don M. Bailey	President and Chief Executive Officer	220,000
Stephen L. Cartt	Executive Vice President, Corporate Development	100,000
Steven Halladay, Ph.D.	Senior Vice President, Clinical and Regulatory Affairs	40,000
David J. Medeiros	Senior Vice President, Pharmaceutical Operations	70,000
Gary M. Sawka <sup>(1)</sup>	Senior Vice President, Finance and Chief Financial Officer	10,000

(1) Mr. Sawka commenced employment with the Company on September 10, 2008.

### Determination of 2009 Base Salaries

On February 26, 2009, the Board, based on the recommendation of the Compensation Committee, approved the 2009 base salaries for the Company's executive officers.

The table below sets forth the 2009 base salary levels for the following executive officers:

<u>Name</u>	<u>Title</u>	<u>2009 Salary</u>
Don M. Bailey	President and Chief Executive Officer	\$546,000
Stephen L. Cartt	Executive Vice President, Corporate Development	\$364,000
Steven Halladay, Ph.D.	Senior Vice President, Clinical and Regulatory Affairs	\$303,850
David J. Medeiros	Senior Vice President, Pharmaceutical Operations	\$338,000
Gary M. Sawka	Senior Vice President, Finance and Chief Financial Officer	\$260,000

### Determination of 2009 Cash Bonus Target Levels for Executive Officers

On February 26, 2009, the Board, based on the recommendation of the Compensation Committee, approved the 2009 cash bonus target levels for the Company's executive officers. The actual amount of cash bonuses that may be awarded remains subject to the discretion of the Board. The table below sets forth the 2009 target bonus percentages for the following executive officers:

<u>Name</u>	<u>Title</u>	<u>2009 Bonus Targets(1)</u>
Don M. Bailey	President and Chief Executive Officer	65%
Stephen L. Cartt	Executive Vice President, Corporate Development	55%
Steven Halladay, Ph.D.	Senior Vice President, Clinical and Regulatory Affairs	45%
David J. Medeiros	Senior Vice President, Pharmaceutical Operations	45%
Gary M. Sawka	Senior Vice President, Finance and Chief Financial Officer	45%

(1) Targets are expressed as a percentage of the officer's 2009 base salary.

---

**SIGNATURES**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2009

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Gary M. Sawka  
Gary M. Sawka  
Senior Vice President, Finance, and Chief Financial  
Officer